Posters

New visual acuity charts: preliminary study on children with ophthalmopathology

Poster Details

First Author: A.Kazakova RUSSIA

Co Author(s):    I. Medvedev   M. Gracheva   D. Pokrovskiy   S. Rychkova           

Abstract Details

Purpose:

The aim of the study was to compare three charts for visual acuity assessment: Lea-screener chart, new IITP chart with wide-space design, and new IITP-V chart with proportional design, in view of repeatability of test and retest measurements in children with opthalmopathology.

Setting:

Institute for Information Transmission Problems (Kharkevich Institute), Russian Academy of Sciences, Russia, Moscow. Pirogov Russian National Research Medical University (RNRMU), Russia, Moscow.

Methods:

The subjects were 35 children  with ophthalmopathology (light and moderate amblyopia - 21, optic nerve atrophy - 11, retinopathy - 3), average age - 11,4 ± 0,4 years. Visual acuity were assessed twice (test and retest assessment) by means of three visual acuity charts in random order: Lea-screener,  IITP chart with wide-space design, and IITP-V chart with proportional design. The viewing distance was 4 m. If needed, optical correction was provided. The measurements were monocular and binocular.

Results:

The data appeared to be not distributed normally (Shapiro–Wilk test, p<0.05), test and retest results were compared by Wilcoxon signed-rank test. Average visual acuities±SE (logMAR), test and retest: 0.33±0.04 and 0.31±0.03 - Lea chart; 0.29±0.03 and 0.28±0.03 - IITP chart; 0.33±0.03 and 0.32±0.27 - IITP-V chart. The results of test and retest were significantly different for LEA chart (p=0.033), which means bad repeatability. No significant difference between test and retest were obtained for IITP and IITP-V charts (p=0.336 and p=0.775, accordingly), which means better repeatability, than in case of Lea chart.

Conclusions:

According to our data, IITP and IITP-V charts show better repeatability in test-retest measurements. Repeatability of results is very important in scientific investigations, visual acuity monitoring, age dynamic assessment and evaluation of treatment results.

Financial Disclosure:

None